Back to Results
First PageMeta Content
Ponatinib / Chronic myelogenous leukemia / Rems / Alkynes / Organofluorides / Piperazines


REMS Document Initial Approval[removed]NDA[removed] Iclusig® (ponatinib) tablets
Add to Reading List

Open Document

File Size: 1,35 MB

Share Result on Facebook

City

Philadelphia / Reference / Cambridge / /

Company

ARIAD / Clinical Oncology Blood New England Journal / Tyrosine Kinase Inhibitor ARIAD Pharmaceuticals Inc. / Kinase Inhibitor ARIAD Pharmaceuticals / Inc. / /

Event

FDA Phase / Man-Made Disaster / /

/

MedicalCondition

positive acute lymphoblastic leukemia / chronic phase / blast phase / chronic myeloid leukemia / thromboembolism / /

Organization

FDA / American Society of Health-System Pharmacists / Hematology Oncology Pharmacy Association / American Society of Hematology / American Society of Clinical Oncology / American Pharmacists Association / Oncology Nursing Society / /

/

Product

Iclusig® (ponatinib) tablets / /

ProvinceOrState

Massachusetts / /

URL

www.IclusigREMS.com / /

SocialTag